wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Templar Virtual EMERGE 4 - RM/SM Quiz

Total questions: 14

Worksheet time: 11mins

Name
Class
Date
1.

Describe the advantage of Rapid Sequencing over Conventional Sequencing in initiating GDMT for HFrEF?

a)

Rapid sequencing focuses on sequential initiation of one drug at a time, allowing slow titration over 6 months or more.

b)

Rapid sequencing introduces all four foundational drugs early, achieving therapeutic coverage within 4 weeks, with dose titration thereafter.

c)

Rapid sequencing recommends starting with ACE inhibitors before β-blockers and SGLT2 inhibitors.

d)

Rapid sequencing omits mineralocorticoid receptor antagonists in the initial phase.

2.

Which neurohormonal pathway plays the most critical role in the progression of chronic heart failure? (More than 1 Answer Correct)

a)

Dopaminergic system

b)

Renin–Angiotensin–Aldosterone System over activation

c)

Sympathetic overdrive

d)

Cholinergic pathway

3.

The benefit of SGLT2 inhibitors in HF is mainly attributed to:

a)

Improved myocardial metabolism

b)

Osmotic diuresis

c)

Reduced preload/afterload

d)

All of the Above

4.

In chronic heart failure, ventricular remodeling happens primarily because of:

a)

Hypertrophy and fibrosis due to neurohormonal activation

b)

Improved myocardial compliance

c)

Reduced preload

d)

Coronary vasodilation

5.

According to the ESC 2023 guidelines, which of the following drug classes has the strongest recommendation (Class Ia) for improving outcomes in patients with HFpEF & HFmrEF?

a)

ARNI (Sacubitril/Valsartan)

b)

MRA (Spironolactone)

c)

SGLT2 inhibitor (Dapagliflozin or Empagliflozin)

d)

GLP-1 receptor agonist

6.

Acute Heart Failure (AHF) is defined as:

a)

A slow improvement in heart function over time

b)

Gradual or rapid change in heart failure signs and symptoms requiring urgent hospitalization

c)

Chronic worsening of hypertension

d)

Any asymptomatic cardiac structural change

7.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is primarily defined as:

a)

Steatotic liver disease caused by high alcohol intake

b)

Steatotic liver disease in the presence of one or more cardiometabolic risk factors and absence of harmful alcohol intake

c)

Any liver disease with elevated liver enzymes

d)

Fatty liver disease only in obese patients

8.

Which of the following statements correctly describes MASH?

a)

MASH is isolated liver steatosis without inflammation

b)

MASH is metabolic dysfunction-associated steatohepatitis with hepatocellular ballooning and lobular inflammation

c)

MASH does not progress to fibrosis or liver cancer

d)

MASH is unrelated to metabolic dysfunction

9.

In the DEAN trial, what was the percentage of patients in the dapagliflozin group who experienced fibrosis improvement without worsening of MASH?

a)

15%

b)

20%

c)

45%

d)

60%

10.

In the DEAN trial, what was the percentage of patients in the dapagliflozin group who achieved MASH resolution without worsening of fibrosis?

a)

8%

b)

15%

c)

23%

d)

30%

11.

As per the Endorse HF sub-study, how much improvement in Ejection Fraction (EF) was seen with dapagliflozin after 1 month?

a)

0%

b)

2%

c)

5%

d)

10%

12.

Type your name

4 lines
13.

Type your Zone

4 lines
14.

Type your Employee ID

4 lines